Drug Trial Radar · NCT04732871
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,720
Actual
Start
Feb 15, 2021
Primary completion
Jun 6, 2022
Study completion Feb 19, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccineBiological
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1Time frame: At Day 1
- Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31Time frame: At Day 31
- Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6Time frame: At Month 6
- Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12Time frame: At Month 12
- Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1Time frame: At Day 1
- Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31Time frame: At Day 31
- Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6Time frame: At Month 6
- Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12Time frame: At Month 12
Locations
46 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Riverside, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
The Villages, Florida
GSK Investigational Site
Evansville, Indiana
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Richfield, Minnesota
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Mt. Pleasant, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Norfolk, Virginia
GSK Investigational Site
Wenatchee, Washington
GSK Investigational Site
Espoo, Finland
GSK Investigational Site
Helsinki, Finland
GSK Investigational Site
Helsinki, Finland
GSK Investigational Site
Jarvenpaa, Finland
GSK Investigational Site
Kokkola, Finland
GSK Investigational Site
Oulu, Finland
GSK Investigational Site
Seinäjoki, Finland
GSK Investigational Site
Tampere, Finland
GSK Investigational Site
Turku, Finland
GSK Investigational Site
Pori, Satakunta, Finland
GSK Investigational Site
Essen, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Mainz, Germany
GSK Investigational Site
München, Germany
GSK Investigational Site
Wallerfing, Germany
GSK Investigational Site
Würzburg, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Goch, North Rhine-Westphalia, Germany
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Kumamoto, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Changhua, Taiwan
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.